Komori
Chordia Therapeutics (190A) · PolicyFirst stated

Strengthening transparency and oversight functions as a company with an Audit and Supervisory Committee

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
An Outside Director-Centered Oversight Structure in Companies with an Audit and Supervisory CommitteeA theme 232 companies write about · 0 as a headwind · 231 as a tailwind

3 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 233 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「We place importance on the interests of the various stakeholders who support our corporate activities. To meet their expectations, we have made strengthening corporate governance an important management priority as we seek to conduct fair and transparent business activities.」

    The company disclosed, for the first time in a form that could be organized into a thread, its approach to strengthening corporate governance through an Audit and Supervisory Committee structure, 5 outside directors, and coordination among internal auditing and financial statement audits.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening transparency and oversight functions as a company with an Audit and Supervisory Committee | Chordia Therapeutics Inc. (190A) | Komori